Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...